product summary
Loading...
company name :
Invitrogen
other brands :
NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience
product type :
antibody
product name :
OVA257-264 (SIINFEKL) peptide bound to H-2Kb Monoclonal Antibody (eBio25-D1.16 (25-D1.16)), eBioscience™
catalog :
14-5743-81
quantity :
50 µg
price :
US 141
clonality :
monoclonal
host :
mouse
conjugate :
nonconjugated
clone name :
eBio25-D1.16 (25-D1.16)
reactivity :
mouse
application :
immunohistochemistry, immunocytochemistry, flow cytometry
more info or order :
Invitrogen product webpage
citations: 27
Published Application/Species/Sample/DilutionReference
  • flow cytometry; mouse; 1:300; loading ...; fig 3b
Sasaki K, Takada K, Ohte Y, Kondo H, Sorimachi H, Tanaka K, et al. Thymoproteasomes produce unique peptide motifs for positive selection of CD8(+) T cells. Nat Commun. 2015;6:7484 pubmed publisher
  • immunocytochemistry; mouse; 1:100; fig 5
Cebrián C, Zucca F, Mauri P, Steinbeck J, Studer L, Scherzer C, et al. MHC-I expression renders catecholaminergic neurons susceptible to T-cell-mediated degeneration. Nat Commun. 2014;5:3633 pubmed publisher
Wang Z, Xu F, Hu J, Zhang H, Cui L, Lu W, et al. Modulation of lactate-lysosome axis in dendritic cells by clotrimazole potentiates antitumor immunity. J Immunother Cancer. 2021;9: pubmed publisher
von Roemeling C, Wang Y, Qie Y, Yuan H, Zhao H, Liu X, et al. Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity. Nat Commun. 2020;11:1508 pubmed publisher
Wang Z, Chen J, Hu J, Zhang H, Xu F, He W, et al. cGAS/STING axis mediates a topoisomerase II inhibitor-induced tumor immunogenicity. J Clin Invest. 2019;129:4850-4862 pubmed publisher
Duan X, Chan C, Han W, Guo N, Weichselbaum R, Lin W. Immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy to eradicate colorectal tumors. Nat Commun. 2019;10:1899 pubmed publisher
Rota G, Ludigs K, Siegert S, Tardivel A, Morgado L, Reith W, et al. T Cell Priming by Activated Nlrc5-Deficient Dendritic Cells Is Unaffected despite Partially Reduced MHC Class I Levels. J Immunol. 2016;196:2939-46 pubmed publisher
Steele S, Radlinski L, Taft Benz S, Brunton J, Kawula T. Trogocytosis-associated cell to cell spread of intracellular bacterial pathogens. elife. 2016;5: pubmed publisher
Tähtinen S, Kaikkonen S, Merisalo Soikkeli M, Grönberg Vähä Koskela S, Kanerva A, Parviainen S, et al. Favorable alteration of tumor microenvironment by immunomodulatory cytokines for efficient T-cell therapy in solid tumors. PLoS ONE. 2015;10:e0131242 pubmed publisher
Dura B, Dougan S, Barisa M, Hoehl M, Lo C, Ploegh H, et al. Profiling lymphocyte interactions at the single-cell level by microfluidic cell pairing. Nat Commun. 2015;6:5940 pubmed publisher
Tellam J, Zhong J, Lekieffre L, Bhat P, Martinez M, Croft N, et al. mRNA Structural constraints on EBNA1 synthesis impact on in vivo antigen presentation and early priming of CD8+ T cells. PLoS Pathog. 2014;10:e1004423 pubmed publisher
Ramakrishnan R, Tyurin V, Tuyrin V, Veglia F, Condamine T, Amoscato A, et al. Oxidized lipids block antigen cross-presentation by dendritic cells in cancer. J Immunol. 2014;192:2920-31 pubmed publisher
Sauer B, Schmalstieg W, Howe C. Axons are injured by antigen-specific CD8(+) T cells through a MHC class I- and granzyme B-dependent mechanism. Neurobiol Dis. 2013;59:194-205 pubmed publisher
Kulpa D, Del Cid N, Peterson K, Collins K. Adaptor protein 1 promotes cross-presentation through the same tyrosine signal in major histocompatibility complex class I as that targeted by HIV-1. J Virol. 2013;87:8085-98 pubmed publisher
Pham C, Woo M, Kim Y, Park S, Kwon M. An anti-nucleic acid antibody delivers antigen to the cross-presentation pathway in dendritic cells and potentiates therapeutic antitumor effects. J Immunol. 2012;189:5755-63 pubmed publisher
Iyori M, Zhang T, Pantel H, Gagne B, Sentman C. TRAIL/DR5 plays a critical role in NK cell-mediated negative regulation of dendritic cell cross-priming of T cells. J Immunol. 2011;187:3087-95 pubmed publisher
Hoves S, Sutton V, Haynes N, Hawkins E, Fernández Ruiz D, Baschuk N, et al. A critical role for granzymes in antigen cross-presentation through regulating phagocytosis of killed tumor cells. J Immunol. 2011;187:1166-75 pubmed publisher
Lim T, Mortellaro A, Lim C, Hämmerling G, Ricciardi Castagnoli P. Mechanical interactions between dendritic cells and T cells correlate with T cell responsiveness. J Immunol. 2011;187:258-65 pubmed publisher
Lorenzi S, Mattei F, Sistigu A, Bracci L, Spadaro F, Sanchez M, et al. Type I IFNs control antigen retention and survival of CD8?(+) dendritic cells after uptake of tumor apoptotic cells leading to cross-priming. J Immunol. 2011;186:5142-50 pubmed publisher
Elliott J, Wahle J, Yokoyama W. MHC class I-deficient natural killer cells acquire a licensed phenotype after transfer into an MHC class I-sufficient environment. J Exp Med. 2010;207:2073-9 pubmed publisher
Xie J, Zhu H, Guo L, Ruan Y, Wang L, Sun L, et al. Lectin-like oxidized low-density lipoprotein receptor-1 delivers heat shock protein 60-fused antigen into the MHC class I presentation pathway. J Immunol. 2010;185:2306-13 pubmed publisher
Yewdall A, DRUTMAN S, Jinwala F, Bahjat K, Bhardwaj N. CD8+ T cell priming by dendritic cell vaccines requires antigen transfer to endogenous antigen presenting cells. PLoS ONE. 2010;5:e11144 pubmed publisher
Stelekati E, Bahri R, D Orlando O, Orinska Z, Mittrücker H, Langenhaun R, et al. Mast cell-mediated antigen presentation regulates CD8+ T cell effector functions. Immunity. 2009;31:665-76 pubmed publisher
Ackerman A, Kyritsis C, Tampe R, Cresswell P. Access of soluble antigens to the endoplasmic reticulum can explain cross-presentation by dendritic cells. Nat Immunol. 2005;6:107-13 pubmed
Berwin B, Hart J, Rice S, Gass C, Pizzo S, Post S, et al. Scavenger receptor-A mediates gp96/GRP94 and calreticulin internalization by antigen-presenting cells. EMBO J. 2003;22:6127-36 pubmed
Messaoudi I, LeMaoult J, Nikolic Zugic J. The mode of ligand recognition by two peptide:MHC class I-specific monoclonal antibodies. J Immunol. 1999;163:3286-94 pubmed
Porgador A, Yewdell J, Deng Y, Bennink J, Germain R. Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity. 1997;6:715-26 pubmed
product information
Product Type :
Antibody
Product Name :
OVA257-264 (SIINFEKL) peptide bound to H-2Kb Monoclonal Antibody (eBio25-D1.16 (25-D1.16)), eBioscience™
Catalog # :
14-5743-81
Quantity :
50 µg
Price :
US 141
Clonality :
Monoclonal
Purity :
Affinity chromatography
Host :
Mouse
Reactivity :
Mouse
Applications :
Flow Cytometry: 0.25 µg/test, Immunohistochemistry: Assay-Dependent
Species :
Mouse
Clone :
eBio25-D1.16 (25-D1.16)
Isotype :
IgG1, kappa
Storage :
4° C
Format :
Liquid
Applications w/Dilutions :
Flow Cytometry: 0.25 µg/test, Immunohistochemistry: Assay-Dependent
Aliases :
H-2Kb-SIINFEKL; OVA257-264; OVA257-264 H-2Kb; OVA-Kb
more info or order :
Invitrogen product webpage
company information
Invitrogen
Thermo Fisher Scientific
81 Wyman Street
Waltham, MA USA 02451
https://www.thermofisher.com
800-678-5599
headquarters: USA